256 related articles for article (PubMed ID: 33541208)
1. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Bullement A; Underhill S; Fougeray R; Hatswell AJ
Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
[TBL] [Abstract][Full Text] [Related]
3. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
[TBL] [Abstract][Full Text] [Related]
4. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Nakashima M; Takeuchi M; Kawakami K
Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821
[TBL] [Abstract][Full Text] [Related]
6. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
7. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
Nakashima M; Takeuchi M; Tanaka S; Kawakami K
Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
[TBL] [Abstract][Full Text] [Related]
9. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
Giuliani J; Bonetti A
Eur J Cancer; 2020 Oct; 138():77-79. PubMed ID: 32871525
[No Abstract] [Full Text] [Related]
12. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
[TBL] [Abstract][Full Text] [Related]
13. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
15. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Giuliani J; Insolda J; Pigozzi E; Bonetti A
Recenti Prog Med; 2020 Dec; 111(12):785-787. PubMed ID: 33362177
[No Abstract] [Full Text] [Related]
18. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani J
Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
